Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep MedicineUnitedHealthcare OSA Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedUnitedHealthcarePolicy 2026T0525VV

    Obstructive and Central Sleep Apnea Treatment

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy 2026T0525VV alerts

    Get alerted when Policy 2026T0525VV changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of diagnostic requirements and nonsurgical and surgical treatments for obstructive sleep apnea and central sleep apnea under UnitedHealthcare Commercial and Individual Exchange benefit plans.

    Policy Summary
    PayerUnitedHealthcare
    PolicyObstructive and Central Sleep Apnea Treatment
    Policy CodePolicy 2026T0525VV
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionDocument PAP failure, refusal, or intolerance before requesting specified surgery or hypoglossal nerve stimulation.
    SourceLink
    POLICY UPDATE CHANGES

    The applicable HCPCS code list was updated to reflect quarterly edits, including the addition of HCPCS code L8697.

    2Applicable benefit plan types
    BMI ≤40Adult hypoglossal nerve stimulation BMI criterion
    15-100Adult hypoglossal nerve stimulation AHI range
    9Unproven or not medically necessary treatment categories
    1HCPCS codes added

    Coverage Criteria

    OSA diagnosis

    Diagnosis of OSA is required before nonsurgical or surgical treatment.

    OSA diagnosis requirements: The individual has symptoms of OSA and has been evaluated in person or by telemedicine before treatment begins by a qualified physician or an Advanced Practice Provider working under the direct supervision of a physician; and OSA is diagnosed and a treatment course is recommended by the qualified physician or appropriately supervised Advanced Practice Provider.

    Removable oral appliances for OSA

    Covered when the diagnosis, objective testing, and prior PAP requirements are met.

    Removable oral appliance: The individual meets the OSA diagnosis requirements; OSA is documented by a sleep study, such as attended polysomnography or home sleep apnea testing; and documentation from the treating physician or Advanced Practice Provider shows that PAP had no therapeutic efficacy or that the individual is intolerant of or has refused PAP.

    Medical necessity criteria are referenced to InterQual CP: Durable Medical Equipment, Noninvasive Airway Assistive Devices.

    Policy Summary
    PayerUnitedHealthcare
    PolicyObstructive and Central Sleep Apnea Treatment
    Policy CodePolicy 2026T0525VV
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionDocument PAP failure, refusal, or intolerance before requesting specified surgery or hypoglossal nerve stimulation.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Documentation and Action ItemsPolicy BackgroundDefinitions

    Adult OSA surgical treatment

    Covered in an adult individual when all of the following are met.

    Adult OSA surgery: The individual has moderate to severe OSA meeting the diagnosis requirements, with AHI ≥ 15 or RDI ≥ 15 determined by attended polysomnography; excessive daytime sleepiness documented by an Epworth Sleepiness Scale score > 10 or another validated tool; and PAP therapy had no therapeutic efficacy or the individual refused or could not tolerate PAP.AHI ≥ 15 or RDI ≥ 15; Epworth Sleepiness Scale > 10

    Additional procedure-specific criteria apply: MMA requires craniofacial disproportion or deformities with evidence of maxillomandibular deficiency; mandibular osteotomy requires retrolingual or lower pharyngeal functional obstruction.

    Adult hypoglossal nerve stimulation

    Covered for adults with moderate to severe OSA when all criteria are met.

    Adult hypoglossal nerve stimulation: The individual is an adult with moderate to severe OSA meeting the diagnosis requirements; BMI is ≤ 40 kg/m²; AHI is ≥ 15 and ≤ 100 by attended polysomnography; total AHI is < 25% for central and mixed apneas; complete blockage or complete concentric collapse of the soft palate is absent on drug-induced sleep endoscopy; PAP had no therapeutic efficacy or the individual refused or could not tolerate PAP; and the device is used in accordance with FDA guidelines.BMI ≤ 40 kg/m²; AHI 15–100; central and mixed apneas < 25% of total AHI

    The device must be FDA-approved.

    Adolescent hypoglossal nerve stimulation

    Covered for adolescents aged 10 to 18 years with Down syndrome when all criteria are met.

    Adolescent hypoglossal nerve stimulation: The adolescent is aged 10 to 18 years and has Down syndrome; severe OSA is documented by attended polysomnogram with AHI ≥ 10 and RDI ≤ 50 events per hour; BMI is below the 95th percentile for age; total AHI for central and mixed apneas is < 25%; prior adenotonsillectomy is contraindicated or was not effective; PAP failure or intolerance is confirmed despite attempts to improve adherence; there is no tracheostomy use during sleep; complete blockage or concentric collapse of the soft palate is absent on drug-induced sleep endoscopy; the individual and caregiver refuse MMA for nonconcentric palatal collapse; and the device is used in accordance with FDA guidelines.AHI ≥ 10; RDI ≤ 50 events/hour; BMI < 95th percentile; central and mixed apneas < 25% of total AHI

    The device must be FDA-approved.

    Central Sleep Apnea Treatments Not Medically Necessary

    Not medically necessary when the requested service is either of the following.

    Unproven central sleep apnea treatments: The requested treatment is an implantable phrenic nerve stimulation device or a removable oral appliance for central sleep apnea.

    Both categories are described as unproven and not medically necessary because of insufficient evidence of safety and/or efficacy.

    Removable oral appliances for central sleep apnea

    Evidence does not support use for CSA.

    Removable oral appliances for CSA: No relevant evidence has been identified to support removable oral appliances for central sleep apnea.

    CSA results from impaired neurological function, whereas oral appliances are designed to manage physical obstruction.

    Prefabricated oral appliances/devices

    Evidence and guidelines are limited.

    Prefabricated oral appliances/devices: Evidence is limited, with a paucity of evidence demonstrating safety or efficacy, and no evidence-based practice guidelines recommend prefabricated devices.

    A randomized trial found custom-made mandibular repositioning devices more effective than ready-made devices for mild to moderate OSA.

    Nonsurgical electrical muscular stimulation

    Evidence is inconclusive.

    Nonsurgical electrical muscular stimulation: Evidence for devices such as eXciteOSA is limited or very low quality and does not establish safety or efficacy for OSA treatment.

    Further randomized controlled trials with long-term outcomes are needed.

    Unestablished oral and repositioning devices

    No quality or published evidence has been identified.

    Unestablished oral or repositioning devices: No quality evidence supports mandibular vertical repositioning devices, epigenetic appliances, or Advanced Lightwire Functional appliances for OSA; no published studies address morning repositioning devices.

    Effects on health outcomes are unknown for morning repositioning devices.

    Adult OSA treatment guidance

    Guideline-supported treatment considerations for adult OSA.

    Positive airway pressure or oral appliance pathway: AASM recommends CPAP or automatic PAP for ongoing adult OSA treatment. For adults intolerant of CPAP or preferring alternate therapy, sleep physicians should consider an oral appliance rather than no treatment.

    When an oral appliance is used, a qualified dentist should provide a custom, titratable appliance with dental oversight and follow-up sleep testing.

    Uvulectomy

    Not supported by sufficient evidence.

    Stand-alone uvulectomy: Uvulectomy performed as a stand-alone procedure for OSA lacks sufficient evidence of effectiveness.

    Published peer-reviewed literature is inadequate to evaluate efficacy.

    Distraction Osteogenesis for Maxillary Expansion

    Not supported by sufficient quality evidence.

    DOME for adult OSA: Distraction osteogenesis for maxillary expansion is not supported by sufficient quality evidence for treatment of adult OSA.

    Available studies are retrospective case series without parallel comparison groups and lack long-term outcomes; randomized controlled trials are lacking.

    Surgical treatment selection

    Guideline-supported clinical selection.

    Surgical treatment of adult OSA

    • UPPP or multilevel surgery: Consider in appropriately selected adults, particularly when PAP is not consistently usable or when multiple upper-airway sites are narrowed and UPPP alone has failed.

      UPPP alone does not reliably normalize AHI in moderate to severe OSA.

    • MMA: Consider for severe OSA when the patient cannot tolerate or is unwilling to adhere to PAP and oral appliances have been ineffective or undesirable.Severe OSA

      Evidence is very low quality and recommendations for mild or moderate OSA are unclear.

    • RFA: May be considered for mild to moderate OSA when PAP cannot be tolerated or is declined and oral appliances are ineffective or undesirable.Mild to moderate OSA

      Evidence is very low quality.

    • LAUP: Not routinely recommended for OSA.

      LAUP generally does not normalize AHI and may worsen AHI in some studies.

    • Palatal implants: May be effective in some patients with mild OSA who cannot tolerate or decline PAP and for whom oral appliances are ineffective or undesirable.Mild OSA

      Available evidence suggests marginal efficacy.

    Hypoglossal nerve stimulation

    Hypoglossal nerve stimulation is considered as a non-first-line or salvage treatment.

    HNS selection: Consider HNS for symptomatic adult OSA when PAP or other recommended noninvasive therapies cannot sufficiently treat the patient; HNS should not generally be first-line therapy.

    ERS suggests salvage HNS when AHI is below 50 events/hour; VA/DoD suggests evaluation at AHI 15–65 events/hour and BMI below 32 kg/m² when PAP cannot be used. AAO-HNS describes HNS as a second-line treatment for moderate to severe OSA with PAP intolerance or lack of benefit.

    Adaptive servoventilation for CHF-related CSAS

    Central sleep apnea syndrome related to congestive heart failure.

    ASV not recommended: Do not use adaptive servoventilation targeted to normalize AHI in adults with CHF-related CSAS when ejection fraction is 45% or less and CSA-predominant sleep-disordered breathing is moderate or severe.LVEF ≤ 45%; moderate or severe CSA-predominant sleep-disordered breathing

    AASM standard against.

    ASV may be used: Adaptive servoventilation targeted to normalize AHI can be used when ejection fraction is greater than 45% or when CHF-related CSAS is mild.LVEF > 45% or mild CHF-related CSAS

    AASM option.

    VA/DoD alternative treatment recommendations

    Alternative treatment recommendations for OSA.

    VA/DoD recommendations: Offer or evaluate selected patients for non-PAP alternatives based on OSA severity and treatment tolerance.

    Mandibular advancement devices may be offered for appropriate mild to moderate OSA with AHI below 30; HNS evaluation may be considered at AHI 15–65 and BMI below 32 when PAP cannot be used; MMA evaluation may be considered for severe OSA when other recommended therapies are unsuitable.

    VA/DoD OSA treatment recommendations

    VA/DoD guideline recommendations for selected patients with OSA.

    Guideline-supported treatment alternatives: For appropriate patients with mild to moderate OSA (AHI < 30 per hour), consider a mandibular advancement device fabricated by a qualified dental provider as an alternative to PAP therapy; for patients with OSA and AHI 15 to 65 per hour and BMI < 32 kg/m² who cannot adhere to PAP therapy, consider evaluation for HNS; for patients with severe OSA who cannot tolerate or are not appropriate candidates for other recommended therapies, consider evaluation for MMA surgery.AHI < 30 per hour; AHI 15–65 per hour with BMI < 32 kg/m²; or severe OSA

    Recommendations are weak and are from the VA/DoD guideline; they are not stated as UnitedHealthcare coverage criteria.

    FDA-described Inspire indications

    FDA-described device indications for selected OSA patients.

    Inspire upper-airway stimulation populations: The FDA-described adult indication includes OSA with baseline AHI from 15 through 100 and BMI up to 40 kg/m², confirmed PAP failure or inability to tolerate PAP, and no complete concentric collapse at the soft palate level. The FDA-described pediatric expansion includes patients aged 13 to 18 years with Down syndrome and severe OSA with AHI 10 through 50 who lack complete concentric palatal collapse and meet the stated adenotonsillectomy, PAP, and alternative-therapy conditions.Adults: AHI 15–100 and BMI up to 40 kg/m²; pediatric Down syndrome: age 13–18 and AHI 10–50

    These are FDA indications presented for informational purposes and do not independently establish coverage.

    The following nonsurgical OSA treatments are unproven and not medically necessary because of insufficient evidence of efficacy: positional OSA devices, nasal dilator devices, intranasal expiratory resistance valves such as Bongo Rx, prefabricated oral appliances or devices, epigenetic appliances, nonsurgical electrical muscular training, mandibular vertical repositioning devices, morning repositioning devices, and Advanced Lightwire Functional appliances.

    The following surgical OSA treatments are unproven and not medically necessary because of insufficient evidence of efficacy: lingual suspension, isolated hyoid myotomy, stand-alone uvulectomy, distraction osteogenesis for maxillary expansion, and transoral robotic surgery.

    Implantable phrenic nerve stimulation devices, including the remedē System, and removable oral appliances for central sleep apnea are unproven and not medically necessary. The policy cites insufficient evidence of safety and/or efficacy for phrenic nerve stimulation and insufficient evidence of efficacy for removable oral appliances.

    Dental services, including CDT codes D9947, D9948, and D9949, are excluded from coverage under the medical plan. Coverage decisions must be based on the member-specific benefit plan document and applicable requirements.

    Evidence regarding hypoglossal nerve stimulation in adolescents with Down syndrome cannot be extrapolated to pediatric individuals without Down syndrome. Additional research is required for that population.

    Stand-alone uvulectomy for OSA lacks sufficient evidence of effectiveness. Published peer-reviewed literature is inadequate to evaluate its efficacy.

    Distraction osteogenesis for maxillary expansion (DOME) is not supported by sufficient quality evidence for adult OSA. Available literature lacks randomized controlled trials establishing safety, efficacy, and long-term outcomes; reported retrospective studies also lack parallel comparison groups and long-term follow-up.

    Laser-assisted uvulopalatoplasty (LAUP) is not routinely recommended for OSA. It generally does not normalize the AHI, has not demonstrated significant improvement in secondary outcomes, and may worsen the overall AHI in some studies.

    For adults with CHF-related central sleep apnea syndrome, adaptive servoventilation targeted to normalize the AHI should not be used when LVEF is ≤ 45% and CSA-predominant sleep-disordered breathing is moderate or severe. It can be used as an option when LVEF is > 45% or when CHF-related CSA is mild.

    FDA approval or 510(k) clearance alone is not a basis for coverage. FDA-described device indications are provided for informational purposes and do not independently establish medical-plan coverage.

    The treatments identified as unproven and not medically necessary are not supported by sufficient evidence of efficacy. For implantable phrenic nerve stimulation for central sleep apnea, the policy also identifies insufficient evidence of safety. These evidence limitations support the policy’s coverage position for the listed OSA and central sleep apnea treatments.

    Implantable phrenic nerve stimulation, including the remedē System, is unproven and not medically necessary for central sleep apnea because of insufficient evidence of safety and/or efficacy.

    Removable oral appliances for central sleep apnea are unproven and not medically necessary because of insufficient evidence of efficacy. Central sleep apnea results from impaired neurological function, while oral appliances are designed to address physical upper-airway obstruction.

    Coding and Clinical Thresholds

    Applicable procedure and HCPCS codesmixed
    0964TImpression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; single arch, without mandibular advancement mechanism.
    0965TImpression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; dual arch, with additional mandibular advancement, non-fixed hinge mechanism.
    0966TImpression and custom preparation of jaw expansion oral prosthesis for obstructive sleep apnea, including initial adjustment; dual arch, with additional mandibular advancement, fixed hinge mechanism.
    21142Reconstruction midface, LeFort I; 2 pieces, segment movement in any direction, without bone graft.
    21199Osteotomy, mandible, segmental; with genioglossus advancement.
    21206Osteotomy, maxilla, segmental (e.g., Wassmund or Schuchard).
    21685Hyoid myotomy and suspension.
    33277Insertion of phrenic nerve stimulator transvenous sensing lead; listed separately in addition to the primary procedure.
    33278Removal of phrenic nerve stimulator, including vessel catheterization, imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s).
    33279Removal of phrenic nerve stimulator, including vessel catheterization, imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only.
    1–10 of 43
    1/5
    Dental services excluded from medical-plan coveragemixedNot Covered
    D9947Dental service code identified as excluded from coverage under the medical plan.
    D9948Dental service code identified as excluded from coverage under the medical plan.
    D9949Dental service code identified as excluded from coverage under the medical plan.
    FDA device and product codesmixed
    LRKFDA product code referenced for oral appliances for obstructive sleep apnea
    LQZFDA product code referenced for oral appliances for obstructive sleep apnea
    K180608FDA 510(k) premarket notification for the Lunoa System
    K180619FDA 510(k) approval for Bongo intranasal appliance
    Added Applicable HCPCS CodeHCPCS
    L8697External accessory for use with implantable phrenic nerve stimulation device, replacement, each.
    Adult moderate-to-severe OSA threshold for specified surgery
    AHI thresholdAHI ≥ 15
    RDI thresholdRDI ≥ 15
    Testing methodDetermined by attended polysomnography
    Excessive daytime sleepiness threshold
    Epworth Sleepiness Scale> 10
    Alternative assessmentAnother validated tool may be used
    ApplicationDocuments excessive daytime sleepiness
    Adult HNS BMI criterion
    Adult HNS BMI criterionBMI ≤ 40 kg/m²
    PopulationAdults with moderate to severe OSA
    Device requirementFDA-approved hypoglossal nerve stimulation device
    Adult HNS AHI range
    Minimum AHIAHI ≥ 15
    Maximum AHIAHI ≤ 100
    Testing methodDetermined by attended polysomnography
    Central and mixed apnea proportion for HNS
    Central and mixed apnea proportionLess than 25% of total AHI
    AssessmentEvaluated by attended polysomnography
    Apnea typesCentral and mixed apneas
    Adolescent HNS OSA severity
    Minimum AHIAHI ≥ 10 events per hour
    Maximum RDIRDI ≤ 50 events per hour
    Testing methodDetermined by attended polysomnogram
    Adolescent HNS BMI
    BMI criterionBMI below the 95th percentile for age
    PopulationAdolescents with Down syndrome
    Age range10 to 18 years
    HNS age groups
    Adult populationAdults
    Adolescent populationAdolescents aged 10 to 18 years with Down syndrome
    Device requirementFDA-approved hypoglossal nerve stimulation device
    Adequate home sleep apnea testing
    Minimum durationAt least 4 hours
    Respiratory sensorsNasal pressure plus chest and abdominal respiratory inductance plethysmography
    OximetryOximetry is required
    Mild OSA definition
    Lower boundaryAHI or RDI ≥ 5
    Upper boundaryAHI or RDI < 15
    ClassificationMild obstructive sleep apnea
    Moderate OSA definition
    Lower boundaryAHI or RDI ≥ 15
    Upper boundaryAHI or RDI ≤ 30
    ClassificationModerate obstructive sleep apnea
    Severe OSA definition
    Severity thresholdAHI or RDI > 30 per hour
    MeasureApnea-Hypopnea Index or Respiratory Disturbance Index
    ClassificationSevere obstructive sleep apnea
    Positional OSA severity in sleep position trainer trial
    AHI rangeAHI 5–30
    OSA severityMild to moderate positional OSA
    Trial interventionSleep position trainer
    Excessive daytime sleepiness threshold
    ESS thresholdESS ≥ 10
    InterpretationExcessive daytime sleepiness
    Assessment toolEpworth Sleepiness Scale
    Position-dependent OSA
    Supine-to-nonsupine relationshipSupine AHI is at least twice the nonsupine AHI
    Nonsupine AHI< 15 events per hour
    ConditionMild or moderate position-dependent OSA
    TEAMUP trial OSA severity
    AHI threshold> 15 events per hour
    OSA severityModerate to severe OSA
    TrialTEAMUP trial
    Moderate OSA in multilevel surgery trial
    AHI range15 to 30 events per hour
    ClassificationModerate OSA
    Study contextMultilevel surgery trial
    Severe OSA in multilevel surgery trial
    AHI threshold> 30 events per hour
    ClassificationSevere OSA
    Study contextMultilevel surgery trial
    STAR trial apnea severity
    AHI thresholdAHI ≥ 15 events per hour
    Apnea severityModerate to severe apnea
    Study contextSTAR trial
    LVEF threshold for ASV in CHF-related CSAS
    LVEF ≤ 45%Do not use adaptive servoventilation for moderate or severe CSA-predominant sleep-disordered breathing
    LVEF > 45%Adaptive servoventilation can be used as an option
    Mild CHF-related CSASAdaptive servoventilation can be used as an option
    AHI for salvage HNS consideration
    AHI threshold< 50 events per hour
    Treatment roleSalvage treatment
    Clinical populationSymptomatic OSA insufficiently treated with CPAP, bilevel PAP, or a mandibular advancement device
    VA/DoD HNS evaluation population
    AHI range15–65 events per hour
    BMI criterionBMI < 32 kg/m²
    PAP statusPatients unable to adhere to PAP
    Lunoa positional OSA indication
    Nonsupine AHI< 20 events per hour
    PopulationAdults with positional OSA
    DeviceLunoa System
    Bongo adult weight indication
    Adult weight> 66 lb
    OSA severityMild to moderate OSA
    DeviceBongo intranasal appliance

    Provider Documentation and Action Items

    Documentation Required

    Document PAP Failure, Intolerance, or Refusal

    Before prescribing a removable oral appliance for OSA, document that PAP therapy produced no therapeutic efficacy, or that the individual is intolerant of or has refused PAP therapy.

    Step Therapy

    PAP Prerequisite for Selected Procedures

    For surgical treatment or implantable hypoglossal nerve stimulation, document the required PAP outcome: no therapeutic efficacy, refusal, or intolerance. Adolescent hypoglossal stimulation requires confirmed PAP failure or intolerance despite attempts to improve adherence.

    Step Therapy

    Consider Noninvasive Therapy Before Alternatives

    Before pursuing surgical or other alternative treatment, document consideration of noninvasive therapy appropriate to the OSA severity and anatomy, including PAP and, when appropriate, a custom oral appliance. Record why these options were unsuccessful, ineffective, undesirable, or not tolerated.

    • CPAP is recommended as initial treatment for moderate to severe OSA.
    • MMA may be considered when PAP cannot be tolerated or oral appliances are ineffective or undesirable.
    • HNS should not be used as first-line treatment and is described as salvage therapy in selected patients.
    Documentation Required

    OSA Evaluation and Diagnosis

    Document an evaluation before treatment and the diagnosis of OSA by a qualified physician or an Advanced Practice Provider working under the direct supervision of a physician.

    • Evaluation may be conducted in person or by telemedicine.
    • Document symptoms, the qualified clinician performing the evaluation, diagnosis, and recommended treatment course.
    Documentation Required

    Sleep-Study Documentation

    Support the OSA diagnosis with a sleep study and retain the report in the medical record before requesting coverage for applicable treatment.

    • Examples include attended polysomnography and home sleep apnea testing.
    • Refer to the Sleep Studies medical policy for additional requirements.
    Documentation Required

    Document PAP Outcome or Intolerance

    For oral appliances, surgery, or hypoglossal nerve stimulation, document the PAP outcome or the individual's refusal or intolerance. For adolescents, document confirmed failure or intolerance despite attempts to improve PAP adherence.

    Documentation Required

    Surgical OSA Criteria Documentation

    For OSA surgery, document the applicable diagnosis, severity, symptoms, sleep-study results, PAP history, and anatomic indication before requesting authorization.

    • For UPPP, mandibular osteotomy, or MMA, document moderate to severe OSA, AHI or RDI ≥ 15, and excessive daytime sleepiness with an Epworth Sleepiness Scale > 10 or another validated tool.
    • For MMA, document craniofacial disproportion or maxillomandibular deficiency.
    • For mandibular osteotomy, document retrolingual or lower-pharyngeal obstruction.
    Documentation Required

    Hypoglossal Stimulation Documentation

    For adult implantable hypoglossal nerve stimulation, submit documentation supporting every applicable clinical criterion and use of an FDA-approved device in accordance with FDA guidelines.

    • BMI ≤ 40 kg/m².
    • AHI 15–100 on attended polysomnography and central/mixed apnea component < 25%.
    • No complete palatal blockage or concentric collapse on drug-induced sleep endoscopy.
    • PAP was ineffective, refused, or not tolerated.
    Documentation Required

    Adolescent Hypoglossal Stimulation Documentation

    For adolescents aged 10–18 years with Down syndrome, document all hypoglossal stimulation criteria, including severe OSA, prior adenotonsillectomy status, PAP failure or intolerance despite adherence efforts, anatomy, and FDA-guideline use.

    • Attended polysomnogram with AHI ≥ 10 and RDI ≤ 50 events/hour.
    • BMI below the 95th percentile for age and central/mixed apnea component < 25%.
    • No tracheostomy use during sleep and no complete or concentric palatal collapse on drug-induced sleep endoscopy.
    • Individual and caregiver refusal of MMA for nonconcentric palatal collapse.
    Documentation Required

    Repeat Polysomnography When Indicated

    Repeat attended polysomnography when clinically significant weight loss or gain, changes in cardiovascular disease, or persistent or recurrent symptoms have occurred since the prior study.

    Documentation Required

    Medical Records for Clinical Review

    Maintain medical records sufficient for clinical review. Records may be requested to determine whether the member meets clinical coverage criteria, but submission does not guarantee coverage.

    • Include evaluation and diagnosis, sleep-study results, severity, symptoms, treatment history, and supporting clinical findings.
    • Coverage remains subject to the member-specific benefit plan and applicable law.
    Billing Rule

    Verify Benefit Plan and Applicable Requirements

    Before providing or billing for treatment, verify the member-specific benefit plan and all applicable federal or state requirements. The benefit plan governs if it conflicts with this policy.

    Documentation Required

    Face-to-Face Specialist Evaluation

    For patients presenting with OSA symptoms, arrange a face-to-face evaluation by a qualified physician trained in otolaryngology-head and neck surgery or sleep medicine, consistent with the cited AAO-HNS position statement.

    Documentation Required

    Oral Appliance Follow-Up

    Arrange ongoing follow-up for oral appliance therapy with a qualified dentist and sleep physician. Follow-up should assess dental or occlusal effects, include periodic office visits, and use follow-up sleep testing to confirm or improve treatment efficacy.

    • Use a custom, titratable appliance when prescribed for an adult with OSA.
    • Document monitoring for dental-related side effects and occlusal changes.
    Documentation Required

    Document OSA Severity, Prior Therapy, and Obstruction Site

    For alternative or surgical OSA treatment, document disease severity, prior noninvasive therapy, and the anatomic site of obstruction that supports the proposed intervention.

    • Record AHI or other severity measure and PAP/oral-appliance response.
    • For tongue-based procedures, document tongue-base or hypopharyngeal obstruction when applicable.
    • For multilevel surgery, document narrowing at multiple upper-airway sites.
    Documentation Required

    Document Device-Specific Indication

    Document the indication for the specific device or procedure rather than relying only on a general OSA diagnosis. Clinical records must support the device's policy criteria and intended use.

    • FDA authorization or a product indication does not by itself establish medical-necessity coverage.
    • For positional devices or intranasal devices, document the applicable clinical indication, while noting that these treatments are unproven under this policy.
    Billing Rule

    Verify the Governing Benefit Plan

    Confirm which benefit plan governs the request before making a coverage determination, including whether the policy is being applied to a Medicare Advantage member and whether Medicare guidance applies.

    • The member-specific benefit plan document governs in the event of conflict.
    • Check applicable federal or state mandates and any NCD, LCD, or other Medicare coverage guidance.
    Denial Risk

    Unproven Nonsurgical OSA Treatments

    Do not represent the following nonsurgical treatments as proven or medically necessary under this policy because evidence is insufficient.

    • Devices for positional OSA; nasal dilator devices; intranasal expiratory resistance valves such as Bongo Rx.
    • Prefabricated oral appliances/devices and epigenetic appliances such as Homeoblock or DNA appliances.
    • Nonsurgical electrical muscular training, mandibular vertical repositioning devices such as Slow Wave, morning repositioning devices, and Advanced Lightwire Functional appliances.
    Denial Risk

    Unproven Surgical OSA Treatments

    Do not represent the following surgical procedures as proven or medically necessary for OSA because evidence is insufficient.

    • Lingual suspension, including tongue stabilization, tongue stitch, or tongue fixation.
    • Isolated hyoid myotomy; transoral robotic surgery; and distraction osteogenesis for maxillary expansion.
    Denial Risk

    Unproven Central Sleep Apnea Treatments

    Treatments for central sleep apnea that lack sufficient evidence of safety or efficacy are unproven and not medically necessary under this policy.

    • Implantable phrenic nerve stimulation devices, such as the remedē System.
    • Removable oral appliances for central sleep apnea.

    Unsupported block type: denial_risk éassistant to=json_output_schema code_word mbilu 代时时彩官网кылууjson_output_schema code:

    Denial Risk

    Implantable Phrenic Nerve Stimulation for CSA

    Implantable phrenic nerve stimulation devices, including the remedē System, are unproven and not medically necessary for central sleep apnea because evidence of safety and/or efficacy is insufficient.

    Denial Risk

    Removable Oral Appliances for CSA

    Removable oral appliances for central sleep apnea are unproven and not medically necessary because evidence of efficacy is insufficient.

    Billing Rule

    Dental Services Excluded From Medical-Plan Coverage

    Dental services are excluded from coverage under the medical plan. Reference the member-specific benefit plan before making a coverage or payment determination.

    • Examples include CDT codes D9947, D9948, and D9949.
    • Do not assume that coverage of a medical oral-appliance device extends to dental services.
    Denial Risk

    Stand-Alone Uvulectomy Lacks Sufficient Evidence

    Stand-alone uvulectomy should not be presented as an evidence-supported OSA treatment; published peer-reviewed evidence is inadequate to establish efficacy.

    Denial Risk

    DOME Lacks Sufficient Quality Evidence

    Distraction osteogenesis for maxillary expansion (DOME) lacks sufficient quality evidence to establish safety, efficacy, and long-term outcomes for adult OSA.

    • Published evidence lacks randomized controlled trials and includes limitations such as small samples, no parallel comparison group, and limited long-term follow-up.
    Note

    HNS Requires Special Arrangements Under NICE Guidance

    Under NICE guidance, hypoglossal nerve stimulation for moderate to severe OSA should be used only with special arrangements for clinical management, consent, and research because evidence is limited in quantity and quality.

    Denial Risk

    FDA Authorization Alone Does Not Establish Coverage

    FDA approval or authorization alone does not establish coverage. Coverage remains subject to the member-specific benefit plan, applicable policy criteria, and other requirements.

    Denial Risk

    FDA Approval Does Not Establish Coverage

    FDA approval does not establish coverage for a product or procedure. Verify the applicable benefit plan and document that the request meets UnitedHealthcare's clinical coverage requirements.

    Policy Background

    This policy addresses coverage of diagnostic requirements and nonsurgical and surgical treatments for obstructive sleep apnea (OSA) and central sleep apnea under UnitedHealthcare Commercial and Individual Exchange benefit plans. It includes removable oral appliances, selected upper-airway surgeries, and implantable hypoglossal nerve stimulation. Coverage depends on physician-led diagnosis, objective sleep-study findings, symptom severity, PAP response or tolerance, and procedure-specific anatomic or demographic criteria. The policy also identifies certain OSA and central sleep apnea treatments as unproven and not medically necessary.

    Definitions

    Apnea
    Airflow reductionAt least a 90% decrease in apnea sensor excursions from baseline
    DurationAt least 10 seconds
    TypesObstructive, mixed, or central, based on respiratory effort
    Apnea-Hypopnea Index
    ComponentsApneas plus hypopneas during the entire sleeping period
    CalculationEvents multiplied by 60 and divided by total sleep time in minutes
    UnitEvents per hour
    Central Sleep Apnea
    Respiratory effortDiminished or absent respiratory effort
    ConditionSleep-disordered breathing
    Associated symptomsExcessive daytime sleepiness or frequent nocturnal awakenings
    Home Sleep Apnea Testing
    Testing typeUnattended diagnostic testing
    PurposeAssesses obstructive sleep apnea without determining sleep stage
    Adequate studyAt least 4 hours with nasal pressure, respiratory inductance plethysmography, and oximetry
    Obstructive Sleep Apnea
    DefinitionDecreased or complete halt in airflow despite ongoing effort to breathe
    Mild severityAHI or RDI ≥ 5 and < 15
    Moderate and severe severityModerate: ≥ 15 and ≤ 30; severe: > 30 per hour
    Hypopnea
    DurationAt least 10 seconds
    Airflow reductionAt least 30% reduction in airflow
    Associated findingAt least 3% oxygen-saturation decrease or an arousal
    Respiratory Disturbance Index
    ComponentsApneas, hypopneas, and respiratory effort-related arousals
    CalculationEvents multiplied by 60 and divided by total sleep time in minutes
    UnitEvents per hour
    Oral Appliance
    PurposeTreats snoring or obstructive sleep apnea
    PlacementInserted into the mouth
    TypesPrefabricated or custom made
    Positive Airway Pressure
    MechanismPressurized filtered air keeps the airway open
    DeliveryAn air pump draws in external filtered air
    TypesContinuous PAP, bilevel PAP, autotitrating PAP, and adaptive servoventilation
    Positional Obstructive Sleep Apnea
    DefinitionAHI is lower in the nonsupine position than in the supine position
    ComparisonNonsupine versus supine AHI
    ConditionPositional obstructive sleep apnea
    Central sleep apnea (CSA)
    Underlying causeImpaired neurological function
    Nature of disorderCentral sleep apnea
    Treatment evidenceNo relevant evidence supports removable oral appliances for CSA
    eXciteOSA
    Device typeNoninvasive intraoral electrical muscle stimulation device
    Intended useMild OSA and snoring
    Suggested regimen20 minutes daily while awake for 6 weeks, then once weekly
    Intranasal expiratory resistance valve
    Device typeNasal expiratory positive airway pressure device
    Intended useTreats obstructive sleep apnea
    Provent statusNo longer manufactured as of 2020
    Apnea-hypopnea index (AHI)
    DefinitionNumber of apnea or hypopnea events per hour
    Moderate-to-severe thresholdAHI ≥ 15 indicates moderate to severe apnea in the cited study
    UnitEvents per hour
    Oxygen desaturation index (ODI)
    DefinitionNumber of oxygen desaturations per hour of sleep
    Desaturation thresholdBlood oxygen decreases by at least 4 percentage points from baseline
    UnitEvents per hour of sleep
    remedē System
    Device typeImplantable phrenic nerve stimulation device
    Intended populationAdults with moderate to severe central sleep apnea
    MechanismStimulates the phrenic nerve
    Transvenous phrenic nerve stimulation (TPNS)
    Treatment typeTransvenous stimulation of the phrenic nerve
    SystemUses an implanted system
    Intended useTreats central sleep apnea
    Hypoglossal nerve stimulation (HNS)
    Treatment typeUpper airway stimulation
    Nerve targetedHypoglossal nerve
    Intended useTreats obstructive sleep apnea